NEW
HAVEN, Conn., Aug. 9, 2022
/PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ: TRVI), a
clinical-stage biopharmaceutical company developing an
investigational therapy Haduvio™ (oral nalbuphine
ER) for the treatment of prurigo nodularis (PN) and chronic cough
in adults with idiopathic pulmonary fibrosis (IPF), today announced
it will be presenting at the following investor and medical meeting
conferences:
Senior management at Trevi Therapeutics
will be presenting at August investor and medical meeting
conferences
Stifel Biotech Executive Summer
Summit (In-person)
Date: Tuesday, August 16, 2022
Fireside chat presentation: Jennifer
Good, President and CEO
Time: 9:00 AM ET
The fireside chat is an invitation-only event and will be
available to attending participants.
6th Annual IPF Summit
(In-person)
Date: Monday,
August 29, 2022
Time: 11:00 AM ET
Participation: Thomas
Sciascia, M.D., Chief Medical Officer, Trevi Therapeutics and Toby Maher, MD, Professor of Medicine and
Director of Interstitial Lung Disease at Keck School of Medicine,
University of Southern California, will
host a pre-conference workshop titled "Approaching Chronic Cough
with a Fresh Mindset to Bring New Therapeutics to Light."
Location: Westin Boston Seaport District, Boston MA
For more information about the IPF Summit or to register please
visit: https://ipf-summit.com/
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical
company focused on the development and commercialization of the
investigational therapy Haduvio for the treatment of prurigo
nodularis and chronic cough in adults with idiopathic pulmonary
fibrosis. These conditions share a common pathophysiology that is
mediated through opioid receptors in the central and peripheral
nervous systems.
Founded in 2011, Trevi Therapeutics is headquartered
in New Haven, CT.
About Haduvio
Haduvio, an investigational therapy, is an oral extended-release
(ER) formulation of nalbuphine. Nalbuphine is a mixed ĸ-opioid
receptor agonist and µ-opioid receptor antagonist that has been
approved and marketed as an injectable for pain indications for
more than 20 years in the United
States and Europe. The ĸ-
and µ-opioid receptors are known to be critical mediators of itch,
cough and certain movement disorders. Nalbuphine's mechanism of
action may also mitigate the risk of abuse associated with µ-opioid
agonists because it antagonizes, or blocks, µ-opioid receptors.
Parenteral nalbuphine is not currently scheduled as a controlled
substance by the DEA in the United
States or by regulatory authorities in most of Europe. Trevi intends to propose Haduvio as
the trade name for nalbuphine ER. Nalbuphine ER has been granted
Fast Track designation by the FDA for the treatment of itch in
patients with prurigo nodularis. Its safety and efficacy have not
been evaluated by any regulatory authority.
Investor Contact
Katie
McManus
Trevi Therapeutics, Inc.
203-304-2499
k.mcmanus@trevitherapeutics.com
Media Contact
Rosalia
Scampoli
914-815-1465
rscampoli@marketcompr.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/trevi-therapeutics-to-present-at-upcoming-august-conferences-301601734.html
SOURCE Trevi Therapeutics, Inc.